" class="no-js "lang="en-US"> Catherine Bianchi, Saint-Gobain, on Pharmaceutical Products
Sunday, May 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

March 8 2023

Catherine Bianchi, Saint-Gobain, on Pharmaceutical Products

In the video, Catherine Bianchi, Marketing Group Leader of Bioprocess Solutions at Saint-Gobain, introduces the products her company is showcasing at the Pharmapack Europe 2023 event. She begins by discussing the company’s single-use systems, including bioprocess bags and tubing, which are used for the storage and transport of biological materials.

Bianchi highlights the importance of sustainability within the industry and explains how Saint-Gobain’s single-use systems are designed to meet environmental requirements and can be customized to fit specific customer needs.

In conclusion, Bianchi emphasizes the importance of high-quality and reliable single-use systems, tubing, and external components in the biopharmaceutical industry and how Saint-Gobain is committed to providing these products to its customers in line with its sustainability goals.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On